STOCK TITAN

[6-K] CureVac N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

CureVac N.V. announced it convened an extraordinary general meeting of shareholders to be held on November 25, 2025 and made related materials available.

The materials include a convening notice with agenda and explanatory notes, a voting proxy, a merger proposal, and explanatory notes to the merger proposal. The information was furnished on Form 6-K and is not deemed “filed” or incorporated by reference under U.S. securities laws.

CureVac N.V. ha annunciato di aver convocato un'assemblea generale straordinaria degli azionisti da tenersi il 25 novembre 2025 e di aver reso disponibili i materiali correlati.

I materiali includono un avviso di convocazione con l'agenda e note esplicative, una procura per voto, una proposta di fusione e note esplicative alla proposta di fusione. Le informazioni sono state fornite mediante Form 6-K e non sono considerate “depositate” o incorporate per riferimento ai sensi delle leggi statunitensi sui valori mobiliari.

CureVac N.V. anunció que convocó una junta general extraordinaria de accionistas para celebrarse el 25 de noviembre de 2025 y puso a disposición los materiales relacionados.

Los materiales incluyen un aviso de convocatoria con agenda y notas explicativas, un poder de voto, una propuesta de fusión y notas explicativas a la propuesta de fusión. La información fue presentada en el Formulario 6-K y no se considera “presentada” ni incorporada por referencia de acuerdo con las leyes de valores de Estados Unidos.

CureVac N.V.은 주주를 대상으로 하는 특별주주총회를 2025년 11월 25일에 개최하기로 소집했다고 발표했고 관련 자료를 제공했습니다.

자료에는 의제와 해설이 수록된 소집 통지서, 의결 대리권, 합병 제안, 및 합병 제안에 대한 설명 주석이 포함됩니다. 정보는 Form 6-K에 제공되었으며 미국 증권법상 “제출된” 것으로 간주되거나 참조에 의해 통합된 것으로 보지 않습니다.

CureVac N.V. a annoncé avoir convoqué une assemblée générale extraordinaire des actionnaires qui se tiendra le 25 novembre 2025 et a mis à disposition les documents connexes.

Les documents incluent un avis de convocation avec l'ordre du jour et des notes explicatives, une procuration de vote, une proposition de fusion et des notes explicatives à la proposition de fusion. L'information a été fournie sur le formulaire 6-K et n'est pas réputée « déposée » ou incorporée par référence au titre des lois américaines sur les valeurs mobilières.

CureVac N.V. gab bekannt, dass sie eine außerordentliche Hauptversammlung der Aktionäre einberufen hat, die am 25. November 2025 stattfinden wird, und stellte damit verbundene Unterlagen zur Verfügung.

Zu den Unterlagen gehören eine Einberufungsnotiz mit Tagesordnung und Erläuterungen, eine Stimmrechtsvertretung, ein Fusionsantrag und Erläuterungen zum Fusionsantrag. Die Informationen wurden in Formular 6-K bereitgestellt und gelten nach US-Wertpapiergesetzen nicht als „eingereicht“ oder durch Bezugnahme einbezogen.

أعلنت CureVac N.V. أنها دعت إلى عقد اجتماع جمعية عمومية استثنائية للمساهمين ليُعقد في 25 نوفمبر 2025 وتوفير المواد ذات الصلة.

تشمل المواد إشعار الدعوة مع جدول الأعمال وملاحظات توضيحية، وتوكيل تصويت، واقتراح الاندماج، وملاحظات توضيحية على اقتراح الاندماج. تم تقديم المعلومات في النموذج 6-K ولا تعتبر “مُقدمة” أو مدرجة بالمرجع وفقاً لقوانين الأوراق المالية الأمريكية.

Positive
  • None.
Negative
  • None.

Insights

EGM announced with a merger proposal; details not in excerpt.

CureVac set an extraordinary general meeting for November 25, 2025, distributing a convening notice, voting proxy, and a merger proposal with explanatory notes. These documents frame what shareholders will be asked to approve.

The excerpt lists document types but provides no transaction terms, valuation, or structure, so potential effects on ownership, strategy, or cash are not described here. The Form 6-K is furnished, not filed, which limits certain liability and incorporation by reference.

Actual implications hinge on the merger proposal’s specifics and the outcomes of the November 25, 2025 meeting, which are not included in the provided text.

CureVac N.V. ha annunciato di aver convocato un'assemblea generale straordinaria degli azionisti da tenersi il 25 novembre 2025 e di aver reso disponibili i materiali correlati.

I materiali includono un avviso di convocazione con l'agenda e note esplicative, una procura per voto, una proposta di fusione e note esplicative alla proposta di fusione. Le informazioni sono state fornite mediante Form 6-K e non sono considerate “depositate” o incorporate per riferimento ai sensi delle leggi statunitensi sui valori mobiliari.

CureVac N.V. anunció que convocó una junta general extraordinaria de accionistas para celebrarse el 25 de noviembre de 2025 y puso a disposición los materiales relacionados.

Los materiales incluyen un aviso de convocatoria con agenda y notas explicativas, un poder de voto, una propuesta de fusión y notas explicativas a la propuesta de fusión. La información fue presentada en el Formulario 6-K y no se considera “presentada” ni incorporada por referencia de acuerdo con las leyes de valores de Estados Unidos.

CureVac N.V.은 주주를 대상으로 하는 특별주주총회를 2025년 11월 25일에 개최하기로 소집했다고 발표했고 관련 자료를 제공했습니다.

자료에는 의제와 해설이 수록된 소집 통지서, 의결 대리권, 합병 제안, 및 합병 제안에 대한 설명 주석이 포함됩니다. 정보는 Form 6-K에 제공되었으며 미국 증권법상 “제출된” 것으로 간주되거나 참조에 의해 통합된 것으로 보지 않습니다.

CureVac N.V. a annoncé avoir convoqué une assemblée générale extraordinaire des actionnaires qui se tiendra le 25 novembre 2025 et a mis à disposition les documents connexes.

Les documents incluent un avis de convocation avec l'ordre du jour et des notes explicatives, une procuration de vote, une proposition de fusion et des notes explicatives à la proposition de fusion. L'information a été fournie sur le formulaire 6-K et n'est pas réputée « déposée » ou incorporée par référence au titre des lois américaines sur les valeurs mobilières.

CureVac N.V. gab bekannt, dass sie eine außerordentliche Hauptversammlung der Aktionäre einberufen hat, die am 25. November 2025 stattfinden wird, und stellte damit verbundene Unterlagen zur Verfügung.

Zu den Unterlagen gehören eine Einberufungsnotiz mit Tagesordnung und Erläuterungen, eine Stimmrechtsvertretung, ein Fusionsantrag und Erläuterungen zum Fusionsantrag. Die Informationen wurden in Formular 6-K bereitgestellt und gelten nach US-Wertpapiergesetzen nicht als „eingereicht“ oder durch Bezugnahme einbezogen.

أعلنت CureVac N.V. أنها دعت إلى عقد اجتماع جمعية عمومية استثنائية للمساهمين ليُعقد في 25 نوفمبر 2025 وتوفير المواد ذات الصلة.

تشمل المواد إشعار الدعوة مع جدول الأعمال وملاحظات توضيحية، وتوكيل تصويت، واقتراح الاندماج، وملاحظات توضيحية على اقتراح الاندماج. تم تقديم المعلومات في النموذج 6-K ولا تعتبر “مُقدمة” أو مدرجة بالمرجع وفقاً لقوانين الأوراق المالية الأمريكية.

CureVac N.V.宣布已召集一场股东的特别股东大会,定于2025年11月25日举行,并提供相关材料。

材料包括带有议程和说明性注释的召集通知、投票授权书、并购提案以及对并购提案的说明性注释。这些信息已在 Form 6-K 上提交,且不被视为在美国证券法下“已提交”或经参照纳入。

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

 

Commission File Number: 001-39446

 

 

CureVac N.V. 

(Exact Name of Registrant as Specified in Its Charter)

 

 

Friedrich-Miescher-Strasse 15, 72076 

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x           Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨           No x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨           No x

 

 

On October 24, 2025, CureVac N.V. (the “Company”) convened an extraordinary general meeting of shareholders to be held on November 25, 2025 and made available to its shareholders certain other materials in connection with such meeting.

 

The information included in this Form 6-K (including Exhibit 99.1, Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CureVac N.V.
  (Registrant)
   
Date: October 24, 2025 By: /s/ Alexander Zehnder
    Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT NO.   DESCRIPTION
99.1   Convening notice to the extraordinary general meeting of shareholders including agenda and explanatory notes.
99.2   Voting proxy.
99.3   Merger proposal
99.4   Explanatory notes to the merger proposal

 

 

 

 

FAQ

What did CureVac (CVAC) announce in this Form 6-K?

CureVac convened an extraordinary general meeting of shareholders for November 25, 2025 and made related meeting materials available.

What documents did CureVac (CVAC) release for the EGM?

A convening notice with agenda and explanatory notes, a voting proxy, a merger proposal, and explanatory notes to the merger proposal.

Is the information in the CureVac (CVAC) Form 6-K considered "filed"?

No. It was furnished on Form 6-K and is not deemed “filed” or incorporated by reference under the Exchange Act or Securities Act.

When is CureVac’s extraordinary general meeting scheduled?

The extraordinary general meeting is scheduled for November 25, 2025.

Who signed the CureVac Form 6-K for CVAC?

It was signed by Alexander Zehnder, Chief Executive Officer, dated October 24, 2025.

Which annual report form does CureVac (CVAC) use?

CureVac files annual reports on Form 20-F.
Curevac B.V.

NASDAQ:CVAC

CVAC Rankings

CVAC Latest News

CVAC Latest SEC Filings

CVAC Stock Data

1.21B
96.00M
57.37%
6.52%
0.38%
Biotechnology
Healthcare
Link
Germany
Tübingen